Treatment for cancer
a technology for cancer and compositions, applied in the field of tumour treatment, can solve the problems of major problems associated with paclitaxel therapy, hinder the ongoing efficacy of paclitaxel treatment, and develop side effects
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Benefits of technology
Problems solved by technology
Method used
Image
Examples
example 1
Paclitaxel and Albendazole Administration to Human Ovarian Carcinoma Cells
[0120]Human ovarian carcinoma cell lines OVCAR-3, SKOV-3, 1A9 and 1A9PTX22 were used. OVCAR-3 and SKOV-3 cells were obtained from the American Type Culture Collection (ATCC) and maintained on RPMI medium and McCoy5A medium respectively according to ATCC instructions. 1A9 is a clone of the human ovarian carcinoma cell line, A2780 (Sackett et al., 1997). 1A9PTX22 is a paclitaxel resistant subclone of 1A9 cells, isolated as an individual clone in a single step selection by exposing 1A9 cells to 5 ng / ml paclitaxel in the presence of 5 μg / ml verapamil, a Pgp antagonist (Giannakakou et al., 1997). Cells were maintained in 15 ng / ml paclitaxel and 5 μg / ml verapamil continuously.
[0121]Sulforhodamine B (SRB) colorimetric assay was used to study the effect of albendazole, paclitaxel or their combination on tumour cell cytotoxicity in vitro.
[0122]Cells were harvested from exponential phase cultures by trypsinizabon, count...
example 2
Cross Resistance in Paclitaxel Resistant Cell Line
[0128]Taxoids, such as paclitaxel, are one class of antimitotic drugs that target tubulin. A further well-characterized class of tubulin-binding drugs are the Vinca alkaloids, exemplified by vincristine, vinblastine and vinorelbine. The Vinca alkaloids interfere with a cells ability to properly form the mitotic spindle by preventing the normal polymerization of microtubules. They have importance in the treatment of leukemia, lymphomas, small cell lung cancer, and other malignancies. A third class of anti-tubulin drugs, exemplified by colchicine, is comprised of a structurally diverse collection of small molecules that are related by the fact that all bind to a common site on tubulin known as the colchicine site and prevent the normal polymerization of microtubules.
[0129]As described above in Example 1, the present inventors have shown that the paclitaxel resistant cell line 1A9PTX22 displays increased sensitivity to the antiprolifera...
example 3
Compositions for Treatment
[0131]In accordance with the best mode of performing the invention provided herein, specific preferred compositions are outlined below. The following are to be construed as merely illustrative examples of compositions and not as a limitation of the scope of the present invention in any way.
Example 3(A)
Composition for Parenteral Administration
[0132]A composition for parenteral injection could be prepared to contain 0.05 mg to 5 g of albendazole and 0.05 mg to 5 g of paclitaxel in 10 mls to 2 litres of 0.1-10% carboxymethylcellulose.
[0133]Similarly, a composition for intravenous infusion may comprise 250 ml of sterile Ringer's solution, and 0.05 mg to 5 g of albendazole and 0.05 mg to 5 g of paclitaxel.
PUM
| Property | Measurement | Unit |
|---|---|---|
| OD | aaaaa | aaaaa |
| compositions | aaaaa | aaaaa |
| drug resistance | aaaaa | aaaaa |
Abstract
Description
Claims
Application Information
Login to View More